Roxifiban
Alternative Names: DMP 754; DMP 755; DPC 754; Lumaxis; MK 0853; XJ 754; XV 459Latest Information Update: 28 May 2007
At a glance
- Originator Bristol-Myers Squibb
- Class Antiplatelets
- Mechanism of Action GPIIb-IIIa antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cardiovascular disorders; Heparin-induced thrombocytopenia and thrombosis syndrome; Peripheral arterial disorders; Thrombosis